First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Machine translation Machine translation
类别 Primary study
期刊International journal of antimicrobial agents
Year 2010
这项研究的目标包括:(i)第一剂量和稳态哌拉西林管理的间断或连续给药的危重患者败血症及(ii)使用群体药代动力学进行蒙特卡洛血药浓度 - 时间曲线比较定量模拟不同哌拉西林给药方案对重症监护病房中经常遇到的细菌病原体,以评估目标实现的可能性(PTA)的最低抑菌浓度(MIC)。采集血浆样品1和2天的治疗,16个危重病人,有8例患者接受间歇静脉推注剂量和8例患者接受持续滴注哌拉西林他唑巴坦(管理)。群体药代动力学模型的开发利用NONMEM,发现二室群体药代动力学模型最好的描述数据。身体总重量被发现与药物清除被列入最终的模型。此外,2000危重病人的药效学评价PTA MIC [(未绑定)浓度保持高于50%(50%F(T> MIC))],并发现,连续给药间隔的MIC模拟输液维持优于免费哌拉西林浓度比单次注射整个给药间隔。配料模拟显示,政府的16g/day的持续静脉滴注与静脉推注给药(每6h4克)提供了卓越的成就,药效终点由MIC(PTA)在93%和53%,分别。这些数据表明,哌拉西林给药持续输注,负荷剂量,第一剂量,并与传统的丸剂药量相比,随后的剂量达到优越的药效​​学目标。
Epistemonikos ID: e3caf97525b014567c1a85e447fa559ead48679f
First added on: Apr 22, 2013
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use